6833 Stock Overview
An investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Sinco Pharmaceuticals Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.18 |
| 52 Week High | HK$0.32 |
| 52 Week Low | HK$0.16 |
| Beta | 0.91 |
| 1 Month Change | 0.55% |
| 3 Month Change | -15.67% |
| 1 Year Change | -25.00% |
| 3 Year Change | -90.27% |
| 5 Year Change | -47.71% |
| Change since IPO | -77.13% |
Recent News & Updates
Lacklustre Performance Is Driving Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 26% Price Drop
Nov 20
What Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 32% Share Price Gain Is Not Telling You
Oct 04Risks To Shareholder Returns Are Elevated At These Prices For Sinco Pharmaceuticals Holdings Limited (HKG:6833)
Aug 16Recent updates
Lacklustre Performance Is Driving Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 26% Price Drop
Nov 20What Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 32% Share Price Gain Is Not Telling You
Oct 04Risks To Shareholder Returns Are Elevated At These Prices For Sinco Pharmaceuticals Holdings Limited (HKG:6833)
Aug 16Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings
Apr 02Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks
Mar 08Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?
Nov 07A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)
Jun 26Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?
May 30Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet
Oct 26Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today
Feb 04I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease
Oct 25Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings
Jun 10Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt
May 24Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock
Apr 20We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings
Feb 16How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 11
Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?
Dec 07Shareholder Returns
| 6833 | HK Healthcare | HK Market | |
|---|---|---|---|
| 7D | -1.1% | -1.3% | -0.5% |
| 1Y | -25.0% | -17.8% | 19.9% |
Return vs Industry: 6833 underperformed the Hong Kong Healthcare industry which returned -17.8% over the past year.
Return vs Market: 6833 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
| 6833 volatility | |
|---|---|
| 6833 Average Weekly Movement | 10.4% |
| Healthcare Industry Average Movement | 8.3% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 6833 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6833's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 303 | Min Jin | www.sinco-pharm.com |
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. It offers Octapharma, a human albumin solution for use in premature infants; Axetine, which is used for the treatment of bacterial infections, including respiratory infections, urinary tract infections, soft tissue infections, gynecological and obstetrical infections, gonorrhea, and other infections, as well as for the prevention of post-surgery infections; and Medocef that is used for the treatment of bacterial infections, such as pneumonia, urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and sepsis. The company also provides Esafosfina, which is used for treating hypophosphatemia and chronic diseases comprising alcohol intoxication, malnutrition, and hypophosphatemic respiratory failure; Taurolite, an oral cholic acid drug that is used for the treatment of gallstone diseases; and Tamifil injection for the treatment of metastatic prostate cancer, true precocious puberty, and endometriosis.
Sinco Pharmaceuticals Holdings Limited Fundamentals Summary
| 6833 fundamental statistics | |
|---|---|
| Market cap | HK$372.02m |
| Earnings (TTM) | HK$49.69m |
| Revenue (TTM) | HK$3.17b |
7.5x
P/E Ratio0.1x
P/S RatioIs 6833 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6833 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.98b |
| Cost of Revenue | CN¥2.63b |
| Gross Profit | CN¥343.95m |
| Other Expenses | CN¥297.32m |
| Earnings | CN¥46.63m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.023 |
| Gross Margin | 11.55% |
| Net Profit Margin | 1.57% |
| Debt/Equity Ratio | 50.8% |
How did 6833 perform over the long term?
See historical performance and comparisonDividends
2.0%
Current Dividend Yield15%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 05:33 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sinco Pharmaceuticals Holdings Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Milo Liu | China Merchants Securities (HK) Co., Ltd |